Febrile neutropenia: Prophylactic and therapeutic use of GM-CSF

European Journal of Cancer

Volumn 35, Issue SUPPL. 3, 1999, Pages 4-7

  Mangi, M H ^a   Newland, A C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; FEBRILE NEUTROPENIA; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; INFECTION; MYCOSIS; PRIORITY JOURNAL; SOLID TUMOR;

ECONOMICS, PHARMACEUTICAL; FEVER; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MYCOSES; NEUTROPENIA; OPPORTUNISTIC INFECTIONS;

EID: 0032805526     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00081-7     Document Type: Conference Paper

References (28)

1. Bodey G.P., Buckley M., Sathe Y.S.et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 64:1966;328-340.
2. Levine A.S., Siegel S.E., Schreiber A.D.et al. Protective environment and prophylactic antibiotics. a prospective controlled study of their utility in the therapy of acute leukemia N. Eng. J. Med. 288:1973;477-483.
3. Pizzo P.A. Management of fever in patients with cancer and treatment induced neutropenia. N. Engl. J. Med. 328:1993;1323-1332.
4. Leischke G.J., Burgess A.W. G-CSF and GM-CSF. N. Eng. J. Med. 327:1992;28-35.
5. Leischke G.J., Burgess A.W. G-CSF and GM-CSF. N. Eng. J. Med. 327:1992;99-106.
6. Bodey G.P., Anaissie E., Gutterman J., Vadhan-Raj S. Role of GM-CSF as adjuvant treatment in neutropenic patients with bacterial and fungal infections. Eur. J. Clin. Microbiol. Infec. Dis. 13(Supp. 2):1994;S18-22.
7. Rowe J.M., Anderson J.W., Mazza J.J.et al. A randomized placebo-controlled phase III study of GM-CSF in adult patients (>55 to 70 years of age) with AML. a study of the Eastern Cooperative Oncology Group (ECOG, E1490) Blood. 86:1995;457-462.
8. Stone R.M., Berg D.T., George S.L.et al. GM-CSF after initial chemotherapy for elderly patients with primary acute myeloid leukemia. N. Engl. J. Med. 22:1995;1671-1677.
9. Lowenberg B., Suciu S., Archimbaud E.et al. Use of GM-CSF during and after remission-induction chemotherapy in patients aged 61 years and older with AML. Blood. 90:1997;2952-2961.
10. Heil G., Hoelzer D., Sanz M.A.et al. A randomized double blind placebo controlled phase III study of filgrastim in remission-induction and consolidation therapy for adults with de novo AML. Blood. 90:1997;4710-4718.
11. Mayordomo J.I., Rivera F., Diaz-Puente M.T.et al. Improving treatment of chemotherapy induced neutropenic fever by administration of colony stimulating factors. J. National Cancer Institute. 87:1995;803-808.
12. Vellenga E., Uyl de Groot C.A., de Wit R.et al. Randomized placebo-controlled trial of GM-CSF in patients with chemotherapy related febrile neutropenia. J. Clin. Oncol. 14:1996;619-627.
13. Anaissie E.J., Vartivarian S., Bodey G.P.et al. Randomized comparison between antibiotics alone and antibiotics plus GM-CSF in cancer patients with fever and neutropenia. Am. J. Med. 100:1996;17-23.
14. Peters B.G., Adkins D.R., Harrison B.R.et al. Antifungal effect of yeast-derived rhu-GM-CSF in patients receiving high dose chemotherapy given with or without autologous stem cell transplantation. A retrospective analysis. Bone Marrow Transplant. 18:1996;93-102.
15. Moore J.J., Herbert L.C., Berger L.A.et al. Adjuvant use of GM-CSF in invasive aspergillosis. Blood. 92(Suppl. 1):1998;335b.
16. Boogaerts M.A., Cavalli F., Cortes-Funes H.et al. Granulocyte growth factors. achieving a consensus Ann. Oncol. 6:1995;237-244.
17. Recommendations for the use of hematopoietic colony stimulating factors. evidence based clinical practice guidelines J. Clin. Oncol. 12:1994;2471-2508.
18. Update of recommendations for the use of hematopoietic colony stimulating factors. evidence based clinical practice guidelines J. Clin. Oncol. 14:1996;1957-1960.
19. Boogaert M.A., Demuynck H.M. Consensus on clinical use of growth factors. Curr. Opin. Hematol. 3:1996;241-246.
20. Smith T.J. Economic analysis of the clinical uses of the colony stimulating factors. Curr. Opin. Hematol. 3:1996;175-179.
21. Desch C.E., Ozer H. Neutropenia and neoplasia. an overview of the pharmacoeconomics of sargramostim in cancer therapy Clin. Ther. 19:1997;847-865.
22. Uyl-de Groot C.A., Lowenberg B., Vellenga E.et al. Cost-effectiveness and quality of life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. Br. J. Haematol. 100:1998;629-636.
23. Hoelzer D. Hematopoietic growth factors - not whether, but when. N. Engl. J. Med. 336:1997;1822-1824.
24. Godwin J.E., Kopecky K.J., Head D.R.et al. Double blind placebo controlled trial of G-CSF in elderly patients with previously untreated AML. a South Western Oncology Group (SWOG) study (9031) Blood. 91:1998;3607-3610.
25. Nemunaitis J., Singer J.W., Buckner C.D.et al. Use of recombinant GM-CSF in autologous transplantation for lymphoid malignancies. Blood. 72:1988;834-836.
26. Witz F., Harousseau J.L., Sadoun A.et al. GM-CSF during and after remission induction treatment for elderly patients with AML. Hematol. Blood Trans. 40:1997;852-856.
27. Hartmann L.C., Tschetter L.K., Habermann T.M.et al. G-CSF in severe chemotherapy induced neutropenia. N. Eng. J. Med. 336:1997;1776-1780.
28. Armitage J.O. Emerging applications of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF). Blood. 92:1998;4491-4508.